Last updated 14 days ago
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
800 patients around the world
Available in Puerto Rico, United States, Brazil
Janssen Research & Development, LLC
2Research sites
800Patients around the world
This study is for people with
Prostate cancer
Castration resistant prostate cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Have histologically confirmed adenocarcinoma of the prostate.Have disease that is metastatic at the time of the screening as determined by the investigator.Participants must receive ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone (GnRH) analog throughout the treatment or have had prior bilateral orchiectomy, and have serum testosterone less than or equal to 50 nanogram per milliliter (ng/dL) (<= 1.73 nanomoles per Liter [nmol/L]) at screening.Have progressed on at least 1 novel androgen receptor pathway inhibition (ARPI) but received no more than 2 different ARPI for any stage of disease.Must have discontinued ARPI before randomization into the study.Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1.
- Known history of either brain or leptomeningeal prostate cancer metastases.Participants with known breast cancer gene 1/2 (BRCA 1/2) mutations (germline or somatic) who have not received treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor, unless not available or contraindicated.Prior or concurrent second malignancy (other than the disease under study) because the natural history or treatment could interfere with study endpoints.Received cytotoxic chemotherapy for prostate cancer in any setting.Received prior treatment with human kallikrein 2 (KLK-2) directed therapies.
Sites
Centro de Estudos e Pesquisas de Hematologia e Oncologia - CEPHO
Recruiting
Pan American Center for Oncology Trials
Recruiting
StudyKLK2-PASenger
SponsorJanssen Research & Development, LLC
Study typeInterventional
Conditions
Castration resistant prostate cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07225946
